Description
DiogenX a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators for the treatment of type one diabetes (T1D)
See the website
Case studies
After raising €27.5M ($30M), DiogenX, a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, wished to increase its visibility and gain market recognition.
Read more